A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents

Clinical Trial Title

Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life: A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents

National Clinical Trial Number:

NCT03816683

Clinical Trial Protocol Description:

The purpose of this observational study is to determine what types of medications patients take to treat mantle cell lymphoma (MCL) as well as how patients respond to those medications. Participating in the study allows for data to be collected on treatments you take for your disease. Data will also be collected on how you respond to the medications chosen by your physician.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have been diagnosed with MCL.
  • Have given informed consent for participation.
  • Are age ≥18 years old, as of the first observed diagnosis of MCL.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Parameswaran Venugopal, MD

Contact Information

Rush Cancer Center Clinical Trials Office